Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675465 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
A Phase 1 study, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02675465 is a Phase 1 study that has completed, run by Amicus Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT02675465, a Phase 1 study, has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
Interventions
- DRUG ATB200
- DRUG AT2221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-04 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675465
The ClinicalTrials.gov registry entry for NCT02675465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ATB200 is the first listed.
NCT02675465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675465 about?
NCT02675465 is a clinical study titled "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221". This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
What is the current status of trial NCT02675465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-04. Estimated completion is 2024-08-22.
What interventions are being tested in trial NCT02675465?
The interventions under investigation include: ATB200 (DRUG), AT2221 (DRUG).
Who is sponsoring clinical trial NCT02675465?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.